enoximone has been researched along with Anesthesia Related Hyperthermia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fiege, M; Gerbershagen, MU; Kolodzie, K; Schulte Am Esch, J; Wappler, F; Weisshorn, R | 1 |
| Brinken, B; Fiege, M; Scholz, J; Schulte am Esch, J; von Richthofen, V; Wappler, F | 1 |
| Fiege, M; Scholz, J; Schulte am Esch, J; von Richthofen, V; Wappler, F; Weisshorn, R | 1 |
| Bergmann, H; Bleese, N; Fiege, M; Kormann, J; Moshar, S; Riess, FC; Wappler, F; Weisshorn, R | 1 |
1 trial(s) available for enoximone and Anesthesia Related Hyperthermia
| Article | Year |
|---|---|
[Diagnosis of susceptibility to malignant hyperthermia with an in vitro contracture test with the phosphodiesterase iii inhibitor enoximone].
Topics: Adolescent; Adult; Child; Child, Preschool; Enoximone; Female; Humans; In Vitro Techniques; Male; Malignant Hyperthermia; Middle Aged; Muscle Contraction; Muscle, Skeletal; Phosphodiesterase Inhibitors | 1998 |
3 other study(ies) available for enoximone and Anesthesia Related Hyperthermia
| Article | Year |
|---|---|
In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Body Temperature; Carbon Dioxide; Cyclic Nucleotide Phosphodiesterases, Type 3; Dose-Response Relationship, Drug; Enoximone; Female; Hydrogen-Ion Concentration; Lactic Acid; Male; Malignant Hyperthermia; Muscle Contraction; Muscle, Skeletal; Phosphodiesterase Inhibitors; Swine | 2003 |
Effects of the phosphodiesterase-III inhibitor enoximone on skeletal muscle specimens from malignant hyperthermia susceptible patients.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adolescent; Adult; Aged; Biopsy; Child; Culture Techniques; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Disease Susceptibility; Dose-Response Relationship, Drug; Enoximone; Female; Humans; Male; Malignant Hyperthermia; Middle Aged; Muscle Contraction; Muscle, Skeletal; Phosphodiesterase Inhibitors; Prospective Studies | 2000 |
Rhabdomyolysis following cardiopulmonary bypass and treatment with enoximone in a patient susceptible to malignant hyperthermia.
Topics: Cardiopulmonary Bypass; Cyclic AMP; Enoximone; Humans; Male; Malignant Hyperthermia; Middle Aged; Muscle Contraction; Phosphodiesterase Inhibitors; Rhabdomyolysis | 2001 |